[{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Leukemia and Lymphoma Society | Kansas Bioscience Authority | Therapeutics for Rare and Neglected Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Auranofin","moa":"Steroid hormone receptor ERR (ESRR)","graph1":"Oncology","graph2":"Phase II","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas Medical Center \/ Leukemia and Lymphoma Society | Kansas Bioscience Authority | Therapeutics for Rare and Neglected Diseases","highestDevelopmentStatusID":"8","companyTruncated":"University of Kansas Medical Center \/ Leukemia and Lymphoma Society | Kansas Bioscience Authority | Therapeutics for Rare and Neglected Diseases"}]
Find Clinical Drug Pipeline Developments & Deals for Auranofin
Details :
Auranofin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Reset All
